Characteristics, Treatment Patterns, and Outcomes of Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Analysis of Health Insurance Claims Data in Germany
The most prevalent treatment approach for MIBC was RC alone (in the absence of NAT or AT). The uptake of new therapeutic options, such as adjuvant nivolumab, in the real world was low, highlighting underutilization of available therapies.
Authors
- Mehmet Burcu (ORCID: https://orcid.org/0000-0003-4572-0987)
- Barthold Deiters (ORCID: https://orcid.org/0000-0002-1630-8080)
- Chethan Ramamurthy (ORCID: https://orcid.org/0000-0003-3935-9638)
- Evi Zhuleku (ORCID: https://orcid.org/0000-0002-5407-019X)
- Antje Mevius (ORCID: https://orcid.org/0000-0002-9556-6693)
- Jennifer S. Stuart
- Patrick Squires
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Wismar University of Applied Sciences (DE)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1007/s40487-025-00413-8
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00